Top Ten most popular articles on Pharmafile.com this week
pharmafile | December 16, 2016 | News story | Medical Communications |Â Â biggest news, biggest stories, top 10, top 10 stories, top stories, top tenÂ
Christmas is nearly here, but there isn’t much Christmas cheer to be had in the pharmaceutical industry. It’s been a rough week for generics companies, who have been indicted in price collusion, and, alongside this, there’s been a reemergence of the price hiking scandal. As if that wasn’t enough, there’s been a few companies that have come a cropper of regulatory watchdogs.
Catch up with the most read stories on Pharmafile.com this week:
10. Former CEO and president of generics company charged with price fixing
Jeffrey Glazer, ex-CEO of Heritage Pharmaceuticals, and Jason Malek, the former president, have been charged with conspiracy to fix prices. The charges come as a result of an ongoing, two-year antitrust investigation by the Justice Department that involves numerous generics companies regarding price changes of different drugs.
9. Phase 3 eye drug combo failure for Novartis
Anti-VEGF eye treatment Lucentis (ranibizumab) was found to be no more effective in treating neovascular age-related macular degeneration (nAMD) when combined with Ophthotech’s anti-PDGF therapy Fovista.
8. Pfizer’s next blockbuster given FDA approval
Pfizer announced that it had received approval for its eczema treatment, Eucrisa, for treatment of patients of two years of age and older. The treatment of mild to moderate atopic dermatitis (AD) is usually treated by a topical steroid but Pfizer’s treatment is new non-steroid treatment.
7. Alexion loses CEO & CFO as internal investigation continues
CEO David Hallal and CFO Vikas Sinha have resigned effective immediately in connection with an internal investigation into improper sales practices.
6. Lonza in $5.5 billion deal to acquire Capsugel
Lonza, the Basel-based supplier to the pharmaceutical, biotech and nutrition industry, has announced that it will acquire Capsugel for $5.5 billion. The transaction is expected to close in the second quarter of 2017 and will see Lonza develop closer manufacturing links with the pharmaceutical industry.
5. Sanofi eyes Actelion merger as J&J backs down
J&J has stepped down from its attempts to acquire the Swiss blood-pressure specialist while Sanofi steps up to the plate.
4. Rare challenges: Meeting patient needs and delivering medical innovation in ultra-rare diseases
Dr Emma Harvey, senior medical director at Alexion Pharmaceuticals UK, shares her views on the challenges of working in the field of ultra-rare diseases and the importance of meeting unmet patient needs.
3. Novartis in collaboration deal worth potential $1.2 billion with Cerulean
Novartis has agreed a collaboration deal with Cerulean Pharma to develop and market potential nanoparticle-drug conjugates, with the deal being worth $1.2 billion depending on milestonse.
2. Obama seals $6.3 billion 21st Century Cures Act
President Barack Obama put the pen to paper on the 21st Century Cures Act on 13 December, which commits to investing $6.3 billion in new spending on a wide range of health related issues over the next decade.
1. Five major pharma firms break ABPI code of conduct, according to watchdog
The Prescription Medicines Code of Practice Authority (PMCPA) has named and shamed five firms for breaching the ABPI’s codes of conduct.
Related Content
Pharmafile.com’s top 10 news stories of the week
Among our ten most-read stories this week: NICE has announced that more patients are eligible …
Pharmafile.com’s top 10 news stories of the week
In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer …
Top Ten most popular articles on Pharmafile.com this week
With just around three weeks until the end of a long year, rapidly emerging news …
